Mesoblast Limited-Product Pipeline Review-2015

Mesoblast Limited-Product Pipeline Review-2015

  • Products Id :- GMDHC07694CDB
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Mesoblast Limited-Product Pipeline Review-2015


Global Markets Direct's, 'Mesoblast Limited-Product Pipeline Review-2015', provides an overview of the Mesoblast Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mesoblast Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Mesoblast Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Mesoblast Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Mesoblast Limited's pipeline products

Reasons To Buy

Evaluate Mesoblast Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Mesoblast Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Mesoblast Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Mesoblast Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mesoblast Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Mesoblast Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Mesoblast Limited Snapshot 5

Mesoblast Limited Overview 5

Key Information 5

Key Facts 5

Mesoblast Limited-Research and Development Overview 6

Key Therapeutic Areas 6

Mesoblast Limited-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Mesoblast Limited-Pipeline Products Glance 11

Mesoblast Limited-Late Stage Pipeline Products 11

Phase III Products/Combination Treatment Modalities 11

Mesoblast Limited-Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Mesoblast Limited-Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Mesoblast Limited-Drug Profiles 14

MPC-06ID 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

MPC-150IM 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

MPC-25Osteo 18

Product Description 18

Mechanism of Action 18

R&D Progress 18


Product Description 20

Mechanism of Action 20

R&D Progress 20

remestemcel-L 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

MPC-25IC 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MPC-300IV 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

MSBCAR-001 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Stem Cell Therapy for Parkinson Disease and Ishemia Stroke 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Synthetic Peptide for Cardiovascular Diseases 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Synthetic Peptide to Inhibit PAI-1 for Cardiovascular Diseases and Oncology 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Mesoblast Limited-Pipeline Analysis 32

Mesoblast Limited-Pipeline Products by Target 32

Mesoblast Limited-Pipeline Products by Route of Administration 33

Mesoblast Limited-Pipeline Products by Molecule Type 34

Mesoblast Limited-Pipeline Products by Mechanism of Action 35

Mesoblast Limited-Recent Pipeline Updates 36

Mesoblast Limited-Dormant Projects 48

Mesoblast Limited-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

Mesoblast Limited, Key Information 5

Mesoblast Limited, Key Facts 5

Mesoblast Limited-Pipeline by Indication, 2015 7

Mesoblast Limited-Pipeline by Stage of Development, 2015 9

Mesoblast Limited-Monotherapy Products in Pipeline, 2015 10

Mesoblast Limited-Phase III, 2015 11

Mesoblast Limited-Phase II, 2015 12

Mesoblast Limited-Preclinical, 2015 13

Mesoblast Limited-Pipeline by Target, 2015 32

Mesoblast Limited-Pipeline by Route of Administration, 2015 33

Mesoblast Limited-Pipeline by Molecule Type, 2015 34

Mesoblast Limited-Pipeline Products by Mechanism of Action, 2015 35

Mesoblast Limited-Recent Pipeline Updates, 2015 36

Mesoblast Limited-Dormant Developmental Projects,2015 48

Mesoblast Limited, Subsidiaries 49

List of Figures

Mesoblast Limited-Pipeline by Top 10 Indication, 2015 7

Mesoblast Limited-Pipeline by Stage of Development, 2015 9

Mesoblast Limited-Monotherapy Products in Pipeline, 2015 10

Mesoblast Limited-Pipeline by Top 10 Target, 2015 32

Mesoblast Limited-Pipeline by Top 10 Route of Administration, 2015 33

Mesoblast Limited-Pipeline by Top 10 Molecule Type, 2015 34

Mesoblast Limited-Pipeline Products by Top 10 Mechanism of Action, 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Mesoblast Limited; Mesoblast Limited-Key Therapeutics; Mesoblast Limited-Pipeline Overview and Promising Molecules; Mesoblast Limited-News; Mesoblast Limited-Latest Updates; Mesoblast Limited-Pipeline; Mesoblast Limited-Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 107820
Site License
USD 3000 INR 215640
Corporate User License
USD 4500 INR 323460



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]